A study identifies FGFR2/3-altered intrahepatic cholangiocarcinoma as a distinct subtype linked to improved disease-specific survival. This research highlights the potential for targeted therapies in this molecularly defined group.
fgfr2 3 altered intrahepatic cholangiocarcinoma a distinct clinicopathologic and molecular subtype associated with improved disease specific survival
Original title: “FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival.”